Uyeki TM, Hui DS, Zambon M et al (2022) Influenza. Lancet 400:693–706. https://doi.org/10.1016/S0140-6736(22)00982-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drake JW (1993) Rates of spontaneous mutation among RNA viruses. Proc Natl Acad Sci U S A 90:4171–4175. https://doi.org/10.1073/pnas.90.9.4171

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taubenberger JK, Kash JC (2010) Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7:440–451. https://doi.org/10.1016/j.chom.2010.05.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dugan HL, Henry C, Wilson PC (2020) Aging and influenza vaccine-induced immunity. Cell Immunol 348:103998. https://doi.org/10.1016/j.cellimm.2019.103998

Article  CAS  PubMed  Google Scholar 

See KC (2022) Vaccination for the prevention of infection among immunocompromised patients: a concise review of recent systematic reviews. Vaccines 10:800. https://doi.org/10.3390/vaccines10050800

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paules CI, Sullivan SG, Subbarao K, Fauci AS (2018) Chasing seasonal influenza—the need for a universal Influenza vaccine. N Engl J Med 378:7–9. https://doi.org/10.1056/NEJMp1714916

Article  PubMed  Google Scholar 

Krammer F, Smith GJD, Fouchier RAM et al (2018) Influenza. Nat Rev Dis Primer 4:3. https://doi.org/10.1038/s41572-018-0002-y

Article  Google Scholar 

Lee JKH, Lam GKL, Shin T et al (2021) Efficacy and effectiveness of high-dose influenza vaccine in older adults by circulating strain and antigenic match: an updated systematic review and meta-analysis. Vaccine 39(Suppl 1):A24–A35. https://doi.org/10.1016/j.vaccine.2020.09.004

Article  CAS  PubMed  Google Scholar 

Gonçalves BC, Lopes Barbosa MG, Silva Olak AP et al (2021) Antiviral therapies: advances and perspectives. Fundam Clin Pharmacol 35:305–320. https://doi.org/10.1111/fcp.12609

Article  CAS  PubMed  Google Scholar 

Pinto LH, Lamb RA (2006) The M2 proton channels of influenza A and B viruses. J Biol Chem 281:8997–9000. https://doi.org/10.1074/jbc.R500020200

Article  CAS  PubMed  Google Scholar 

Kumar G, Sakharam KA (2024) Tackling Influenza A virus by M2 ion channel blockers: latest progress and limitations. Eur J Med Chem 267:116172. https://doi.org/10.1016/j.ejmech.2024.116172

Article  CAS  PubMed  Google Scholar 

Deyde VM, Xu X, Bright RA et al (2007) Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249–257. https://doi.org/10.1086/518936

Article  CAS  PubMed  Google Scholar 

Cheung C-L, Rayner JM, Smith GJD et al (2006) Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J Infect Dis 193:1626–1629. https://doi.org/10.1086/504723

Article  CAS  PubMed  Google Scholar 

Dong G, Peng C, Luo J et al (2015) Adamantane-resistant influenza a viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PLoS ONE 10:e0119115. https://doi.org/10.1371/journal.pone.0119115

Article  CAS  PubMed  PubMed Central  Google Scholar 

Colman PM, Varghese JN, Laver WG (1983) Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41–44. https://doi.org/10.1038/303041a0

Article  CAS  PubMed  Google Scholar 

Read RC (1998) Treating influenza with zanamivir. Lancet 352:1872–1873. https://doi.org/10.1016/S0140-6736(98)00087-7

Article  CAS  PubMed  Google Scholar 

Slain D (2021) Intravenous Zanamivir: A viable option for critically Ill patients with influenza. Ann Pharmacother 55:760–771. https://doi.org/10.1177/1060028020963616

Article  CAS  PubMed  Google Scholar 

Hayden FG, Atmar RL, Schilling M et al (1999) Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336–1343. https://doi.org/10.1056/NEJM199910283411802

Article  CAS  PubMed  Google Scholar 

Scott LJ (2018) Peramivir: a review in uncomplicated influenza. Drugs 78:1363–1370. https://doi.org/10.1007/s40265-018-0981-8

Article  CAS  PubMed  Google Scholar 

Watanabe A, Chang S-C, Kim MJ et al (2010) Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 51:1167–1175. https://doi.org/10.1086/656802

Article  CAS  PubMed  Google Scholar 

Kashiwagi S, Watanabe A, Ikematsu H et al (2016) Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis 63:330–337. https://doi.org/10.1093/cid/ciw255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Samson M, Pizzorno A, Abed Y, Boivin G (2013) Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 98:174–185. https://doi.org/10.1016/j.antiviral.2013.03.014

Article  CAS  PubMed  Google Scholar 

Takashita E, Daniels RS, Fujisaki S et al (2020) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018. Antiviral Res 175:104718. https://doi.org/10.1016/j.antiviral.2020.104718

Article  CAS  PubMed  Google Scholar 

Hurt AC, Nor’e SS, McCaw JM, et al (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84:9427–9438. https://doi.org/10.1128/JVI.00373-10

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abed Y, Goyette N, Boivin G (2004) A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 9:577–581

Article  CAS  PubMed  Google Scholar 

Baranovich T, Saito R, Suzuki Y et al (2010) Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008–2009 season. J Clin Virol 47:23–28. https://doi.org/10.1016/j.jcv.2009.11.003

Article  CAS  PubMed  Google Scholar 

Collins PJ, Haire LF, Lin YP et al (2009) Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317–6323. https://doi.org/10.1016/j.vaccine.2009.07.017

Article  CAS  PubMed  Google Scholar 

Govorkova EA, Takashita E, Daniels RS et al (2022) Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020. Antiviral Res 200:105281. https://doi.org/10.1016/j.antiviral.2022.105281

Article  CAS  PubMed  PubMed Central  Google Scholar